Operator
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited First Quarter 2021 Earnings Conference Call.
[Operator Instructions]
This conference is being recorded today, May 12, 2021. I would now like to turn the conference call over to Mr. Scott Powell, Executive Vice President of Investor Relations. Please go ahead.
Scott Powell
Executive Vice President, Investor Relations & Chief Financial Officer of Volition America, Inc.
Thank you, and welcome everyone to today s earnings conference call for VolitionRx Limited. This call will cover Volition s financial and operating results for the first quarter of 2021, along with a discussion of our recent activities and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question-and-answer session. On our call today are Mr. Cameron Reynolds, President and Chief Executive Officer; Mr. Terig Hughes, our Chief Financial Officer.
Interview with the President and CEO: VolitionRX Ltd (NYSEAMERICAN:VNRX) twst.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from twst.com Daily Mail and Mail on Sunday newspapers.
VolitionRx Limited Opens its New Manufacturing Facility in Belgium
News provided by
Share this article
Share this article
AUSTIN, Texas, Jan. 25, 2021 /PRNewswire/ VolitionRx Limited (NYSE AMERICAN: VNRX) ( Volition ) today announced the opening of Silver One , its 10,000 square foot dedicated manufacturing facility located on the same science park as its Research and Development laboratory in Isnes, Belgium. Volition plans to utilize this facility to produce, at large scale, all the key raw materials for its Nu. Q™ products, such as recombinant nucleosomes and antibodies. Volition will also use the facility to manufacture finished products such as the recently launched Nu.Q™ Vet Cancer Screening Test and the recently CE-marked blood cancer test.
Share this article
Share this article
AUSTIN, Texas, Jan. 6, 2021 /PRNewswire/ VolitionRx Limited (NYSE AMERICAN: VNRX) ( Volition ) today announced it has been awarded additional non-dilutive funding totaling approximately $4 million from the Walloon Region and Namur Invest, Belgium. To date, Agencies from the Walloon Region have awarded Volition an aggregate of approximately $13 million in non-dilutive funding including this most recent award. This additional funding consisted of a cash grant of $1.3 million and $2.7 million in loans. It is a key part of our financing strategy to actively seek non-dilutive funding as this provides additional cash at favorable terms to support the Company s continued development, and this latest funding takes the total non-dilutive funding to-date from all sources to over $15 million, commented Cameron Reynolds, President and Chief Executive Officer of Volition. Mr. Reynolds added, We are delighted with the great progress we are making on s